Drug clinical trial reporting still dangerously inadequate, says BMJ
This article was originally published in SRA
Executive Summary
The British Medical Journal has published seven research papers that provide a damning indictment of current practice in pharmaceutical clinical trial reporting1. According to an accompanying editorial by senior research fellow Richard Lehman and clinical epidemiology editor Elizabeth Loder, the articles confirm that "a large proportion of evidence from human trials is unreported, and much of what is reported is done so inadequately"2. They contend that this leads to unnecessary harm to patients and costs to health systems.
You may also be interested in...
Big Pharma’s Aging Antibodies Cling To Their Crowns
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis To Pay $9.7bn For The Medicines Company
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: